Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CANDEX vs LOTRIMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Hypertension,Heart failure (NYHA class II-IV and left ventricular systolic dysfunction, to reduce cardiovascular mortality)
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis,Vaginal treatment of vulvovaginal candidiasis
Adults: 150 mg orally once daily
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine.
Hepatic metabolism via CYP3A4 and CYP2C9; excreted in feces and urine as metabolites.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
99% bound to albumin (primarily), also to alpha-1-acid glycoprotein.
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails.
Volume of distribution is approximately 2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects.
Topical: minimal systemic absorption (<0.5%). Oral: not available; vaginal: approximately 3-10% systemic absorption.
Cr Cl 30-60 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 50 mg once daily; Cr Cl <15 m L/min: 50 mg every 48 hours
No dose adjustment required for topical or vaginal use. For troches, no data available; however, systemic absorption is minimal.
Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended
No dose adjustment required for topical or vaginal use. For troches, use with caution in severe hepatic impairment due to limited data.
Not established for children <18 years of age
Topical: Apply to affected area twice daily for 2-4 weeks (safe for all ages). Vaginal: Not recommended in prepubertal children. Troches: Not recommended for children under 5 years due to risk of choking; for children ≥5 years, same dose as adults (10 mg troche five times daily).
No specific adjustment required; consider renal function and potential for increased sensitivity
No specific dose adjustment required. Use same dosing as adults. Consider skin fragility with topical application.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None
Fetal toxicity,Hypotension in volume-depleted patients,Renal function impairment,Hyperkalemia,Avoid concomitant use with aliskiren in patients with diabetes
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs; not for ophthalmic or oral use; use in pregnancy only if clearly needed (Category B).
Hypersensitivity to candesartan or any component,Concomitant use with aliskiren in patients with diabetes,Pregnancy
Hypersensitivity to clotrimazole or any component of the formulation
No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium.
No known significant food interactions.
Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation.
Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical application). First trimester vaginal use has insufficient data, but no clear teratogenic signal. Second and third trimester vaginal use is considered safe. Overall, risk is low due to negligible systemic exposure.
Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred.
Minimal systemic absorption after topical or vaginal use leads to negligible excretion into breast milk. M/P ratio is not applicable due to undetectable levels. Suitable for use during breastfeeding. No adverse effects reported in nursing infants.
Pharmacokinetic changes in pregnancy (increased volume of distribution, renal blood flow) may require dose adjustments. However, due to fetotoxicity, candesartan is contraindicated in pregnancy, and no dose recommendation is provided. Alternative antihypertensives such as labetalol or nifedipine are preferred.
No dose adjustment required during pregnancy. Pharmacokinetics of topical/vaginal clotrimazole are unchanged due to minimal systemic absorption. Standard dosing (e.g., 100 mg vaginal tablet for 7 days or 500 mg single dose) is appropriate.
Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment.
Clotrimazole is a broad-spectrum antifungal agent; Topical formulations (cream, solution, lotion) are preferred for dermatophytosis; Vaginal tablets must be inserted high into the vagina; Avoid use on broken or inflamed skin; Monitor for local irritation.
Take exactly as prescribed, usually once daily.,Avoid potassium supplements or salt substitutes containing potassium without medical advice.,If you become pregnant, stop taking and contact your doctor immediately.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Report any signs of angioedema (swelling of face, lips, throat) or fainting.,Stay hydrated, especially if experiencing diarrhea or vomiting.
Apply the medication to the affected area as directed, usually twice daily.,Wash hands before and after application unless treating hands.,For vaginal tablets, insert one tablet deep into the vagina at bedtime for 3 or 7 days.,Complete the full course even if symptoms improve.,Avoid tight-fitting clothing and synthetic fabrics; keep area clean and dry.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CANDEX vs LOTRIMIN, answered by our medical review team.
CANDEX is a Topical Antifungal and Corticosteroid that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.. LOTRIMIN is a Topical Antifungal that works by Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CANDEX and LOTRIMIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CANDEX is: Adults: 150 mg orally once daily. The standard adult dose of LOTRIMIN is: Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CANDEX and LOTRIMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CANDEX is classified as Category C. Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malf. LOTRIMIN is classified as Category C. Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical applicat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.